1
|
Mohamad NE, Hashem N, Eltahlawy S, Gomaa E. Involvement of high-mobility group box-1 and Dermoscopy in diagnosis of psoriasis severity. J Cosmet Dermatol 2022; 21:6336-6342. [PMID: 36054152 DOI: 10.1111/jocd.15282] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 07/13/2022] [Accepted: 07/27/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND/OBJECTIVES The diagnosis of psoriasis is usually established on clinical grounds but there is lacking of such diagnostic tools to stratify its severity. Psoriasis is a chronic inflammatory disease of skin, nails, and joints. Dermoscopy represent a novel diagnostic tool to diagnose and assess psoriasis severity. The main purpose of this study is to assess the value of dermoscopy associated with serum level of high-mobility group box-1 level (HMGB-1) in the diagnosis and stratification of psoriasis severity. METHODS This study included 60 Egyptians subdivided into two equal groups, psoriatic patients, and controls. All patients were subjected first to dermoscopic examination, and then we evaluated the serum levels of HMGB-1 among all studied groups. RESULTS The level of HMGB-1 increased in psoriatic patients than controls. There was significant difference between patients and controls in the serum levels of HMGB -1. There were also a positive significant correlation between HMGB-1 and different stages of disease severity. There were also significant correlations between HMGB-1 and specific dermoscopic findings like vascular pattern and vascular number, erythema grades as well as types of scales (Fine, coarse) and (Fine, thick). CONCLUSIONS Dermoscopy and HMGB-1 can be considered as a combined novel diagnostic tool for psoriasis severity.
Collapse
Affiliation(s)
- Noha Ezzat Mohamad
- Department of Dermatology, STDs and Andrology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
| | - Noha Hashem
- Department of Dermatology, STDs and Andrology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
| | - Samar Eltahlawy
- Department of Dermatology, Faculty of Medicine, Cairo University, Giza, Egypt
| | - Enas Gomaa
- Department of Microbiology and Immunology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
| |
Collapse
|
2
|
Pedić L, Pondeljak N, Šitum M. Recent information on photoaging mechanisms and the preventive role of topical sunscreen products. ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA 2020. [DOI: 10.15570/actaapa.2020.40] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Baran A, Myśliwiec H, Szterling-Jaworowska M, Kiluk P, Świderska M, Flisiak I. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J DERMATOL TREAT 2017; 29:19-23. [PMID: 28498006 DOI: 10.1080/09546634.2017.1330529] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVE YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment. METHODS A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Blood samples were collected before and after 2 weeks of therapy. Serum YKL-40 concentrations were evaluated by enzyme-linked immunosorbent assay (ELISA). The results were correlated with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory and biochemical markers, lipid profile and topical therapy. RESULTS Median YKL-40 serum levels were significantly increased in psoriatic patients in comparison to the controls (p < .0001). No significant correlations between investigated protein and metabolic parameters as BMI (p = .19), glucose (p = .32) nor lipids levels were found. Significant positive relation with CRP (p = .003) or alanine aminotransferase (p = .04) and no correlation with PASI (p = .2) were noted. Serum YKL-40 level remained unchanged (p = .5) after topical treatment, despite clinical improvement. CONCLUSIONS YKL-40 might be a biomarker of psoriasis and inflammation in psoriatic patients, but not a reliable indicator of metabolic conditions, severity of psoriasis nor efficacy of the treatment.
Collapse
Affiliation(s)
- Anna Baran
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - Hanna Myśliwiec
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | | | - Paulina Kiluk
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - Magdalena Świderska
- b Department of Infectious Diseases and Hepatology , Medical University of Bialystok , Bialystok , Poland
| | - Iwona Flisiak
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| |
Collapse
|
4
|
Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol 2016; 12:237-49. [PMID: 26692125 DOI: 10.1586/1744666x.2016.1134319] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show some limits in terms of tolerability and route of administration. Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways. Because of the favorable safety profile and the oral route of administration, apremilast may represent a promising therapeutic target for moderate-to-severe psoriasis. In this review, we report an updated overview about clinical trials testing apremilast in the treatment of psoriasis and seek to provide comprehensive information about this anti-psoriatic drug and a future perspective of the therapeutic algorithm for psoriasis.
Collapse
Affiliation(s)
- Andrea Chiricozzi
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| | - Dante Caposiena
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| | - Virginia Garofalo
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| | - Maria Vittoria Cannizzaro
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| | - Sergio Chimenti
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| | - Rosita Saraceno
- a Dermatology Department, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy
| |
Collapse
|
5
|
Baran A, Świderska M, Bacharewicz-Szczerbicka J, Myśliwiec H, Flisiak I. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis. Lipids 2016; 52:51-60. [PMID: 27864793 PMCID: PMC5222907 DOI: 10.1007/s11745-016-4211-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 11/02/2016] [Indexed: 01/09/2023]
Abstract
Psoriasis is associated with metabolic syndrome and cardiovascular disease. Fatty acid-binding proteins (FABP) have been recognized as predictors of these systemic disorders. The aim of this study was to assess correlations between levels of serum heart and adipocyte fatty acid-binding proteins (FABP3, FABP4) and disease severity, indicators of inflammation or metabolic disturbances, and topical treatment in psoriatic patients. Thirty-seven patients with relapse of plaque-type psoriasis and 16 healthy volunteers were recruited. Blood samples were collected before and after 14 days of therapy. Serum FABP concentrations were examined by enzyme-linked immunosorbent assay for correlation with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory or metabolic parameters, and treatment used. The median FABP4 serum levels were significantly increased (p = 0.038) in psoriatic patients, while FABP3 levels did not differ (p = 0.47) compared to the controls. No significant correlations were noted between the proteins and PASI, C-reactive protein (CRP), BMI, or levels of glucose or lipids. FABP3 significantly correlated with white blood count (p = 0.03) and aspartate aminotransferase (p = 0.04). After topical treatment, there was no significant change in serum FABP3 [11.5 (4.9-30.3) vs. 12.9 (3.5-30.3) ng/ml] (p = 0.96), whereas FABP4 was decreased [27,286 (20,344-32,257) vs. 23,034 (18,320-29,874) pg/ml] (p = 0.12), losing its basal significance. FABP4 may be a marker of psoriasis, and FABP3 may be associated with inflammation or liver disorders in psoriatic patients. FABP do not appear to be useful for determining disease severity or the effectiveness of antipsoriatic treatment.
Collapse
Affiliation(s)
- A Baran
- Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Bialystok, Poland.
| | - M Świderska
- Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St, 15-540, Bialystok, Poland
| | | | - H Myśliwiec
- Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Bialystok, Poland
| | - I Flisiak
- Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Bialystok, Poland
| |
Collapse
|
6
|
Baran A, Myśliwiec H, Kiluk P, Świderska M, Flisiak I. Serum irisin levels in patients with psoriasis. J DERMATOL TREAT 2016; 28:304-308. [PMID: 27786588 DOI: 10.1080/09546634.2016.1254327] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND Irisin has been proposed to regulate metabolic diseases such as obesity, diabetes or metabolic syndrome which are common comorbidities in psoriasis. OBJECTIVES The aim of this study was to evaluate the serum irisin level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and topical treatment. METHODS Thirty-seven individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Blood samples were collected before and after two weeks of therapy. Serum irisin concentrations were examined by enzyme-linked immunosorbent assay (ELISA). The results were correlated with psoriasis area and severity index (PASI), body mass index (BMI), inflammatory and biochemical markers, lipid profile and effectiveness of topical treatment. RESULTS Irisin serum levels were insignificantly increased in psoriatic patients in comparison to the controls (p = 0.38). No significant correlations between investigated adipokine and several indicators of metabolic disorders, nor BMI (p = 0.37) or PASI (p = 0.5) were found. Significant positive correlations with C-reactive protein (CRP) (0.009), lipocalin-2 (p = 0.02), age (p = 0.02) and disease duration (p = 0.008) were noted. After topical treatment, serum irisin level did not significantly change (p = 0.31), despite clinical improvement. CONCLUSIONS Irisin might be a marker of inflammation in psoriatic patients, but may not be a reliable indicator of metabolic conditions, severity of psoriasis nor efficacy of antipsoriatic treatment.
Collapse
Affiliation(s)
- Anna Baran
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - Hanna Myśliwiec
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - Paulina Kiluk
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - Magdalena Świderska
- b Department of Infectious Diseases and Hepatology , Medical University of Bialystok , Bialystok , Poland
| | - Iwona Flisiak
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| |
Collapse
|
7
|
Rojo Suárez N, Jiménez Gallo D, Arjona Aguilera C, Espinosa Rosso R, Linares Barrios M. Resolution of inverse psoriasis after treatment with levodopa for Parkinson's disease. Dermatol Ther 2016; 30. [PMID: 27550839 DOI: 10.1111/dth.12408] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Inverse psoriasis is characterized by the development of erythematous shiny plaques at intertriginous areas of the body. It has a prevalence of 2% worldwide. The usefulness of levodopa in psoriasis was discovered in 1970 but nowadays it is not a standard therapy for this condition. A 74-year-old woman was diagnosed with Parkinson's disease subsequent to the development of extensive inverse psoriasis. The skin lesions were resistant to classical topical and systemic medications. Treatment with levodopa was initiated in order to treat her neurological problem and progressive remission of the skin lesions was noted. We highlight the role of dopamine in the pathophysiology of this dermatosis.
Collapse
|
8
|
Abstract
Psoriasis is a chronic inflammatory dermatosis that is thought to onset as a result of T lymphocyte-mediated immunological response. Disease may manifest itself in different modalities with regard to clinical features and severity. Clinical type of psoriasis is an important element in determining the therapy regimen. This article reviews clinical types of psoriasis.
Collapse
|
9
|
Baran A, Świderska M, Myśliwiec H, Flisiak I. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. J DERMATOL TREAT 2016; 28:136-140. [PMID: 27165470 DOI: 10.1080/09546634.2016.1180340] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE Psoriasis has been considered as systemic disorder. Lipocalin-2 might be a link between psoriasis and its comorbidities. Aim of the study was to investigate the associations between serum lipocalin-2 levels and the disease activity, markers of inflammation or metabolic disturbances and changes after topical treatment in psoriatic patients. METHODS Thirty-seven individuals with active plaque-type psoriasis and 15 healthy controls were recruited. Blood samples were collected before and after 14 days of therapy. Serum lipocalin-2 concentrations were examined by enzyme-linked immunosorbent assay. The results were correlated with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory and biochemical markers, lipid profile and with effectiveness of topical treatment. RESULTS Lipocalin-2 serum levels were significantly increased in psoriatic patients in comparison to the controls (p = 0.023). No significant correlations with indicators of inflammation, nor BMI or PASI were noted. A statistical association between lipocalin-2 and low-density lipoprotein-cholesterol was shown. After topical treatment serum lipocalin-2 level did not significantly change (p = 0.9), still remaining higher than in the controls, despite clinical improvement. CONCLUSIONS Lipocalin-2 might be a marker of psoriasis and convey cardiovascular or metabolic risk in psoriatic patients, but may not be a reliable indicator of inflammation, severity of psoriasis nor efficacy of antipsoriatic treatment.
Collapse
Affiliation(s)
- A Baran
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - M Świderska
- b Department of Infectious Diseases and Hepatology , Medical University of Bialystok , Bialystok , Poland
| | - H Myśliwiec
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| | - I Flisiak
- a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland
| |
Collapse
|
10
|
Baran A, Swiderska M, Flisiak I. The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels. J DERMATOL TREAT 2015; 27:114-9. [PMID: 26293108 DOI: 10.3109/09546634.2015.1079300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Psoriasis has been considered as chronic systemic disease. Retinol-binding protein-4 (RBP-4) might play a role in psoriasis and its comorbidities. The aim of this study was to investigate the associations between serum RBP-4 levels and disease severity, indicators of inflammation or metabolic syndrome and changes after topical treatment in psoriatic patients. METHODS Thirty-seven patients with relapse of plaque-type psoriasis and 16 healthy volunteers were examined. Blood samples were collected before and after 14 days of therapy. Serum RBP-4 concentrations were examined by enzyme-linked immunosorbent assay for correlation with psoriasis area and severity index (PASI), body mass index (BMI), inflammatory and biochemical markers and with efficacy of topical treatment. RESULTS RBP-4 serum levels were increased in psoriatics compared to the controls, but without statistical significance (p = 0.2). No significant correlations between investigated adipokine and several indicators of metabolic disorders, nor BMI or PASI were found. A significant negative correlation with CRP was noted. After topical treatment serum RBP-4 level did not significantly change (p = 0.3), despite clinical improvement. CONCLUSION RBP-4 might have a protective role in terms of chronic inflammation and comorbidities of psoriasis. The adipokine is presumably not useful in determining severity and the effectiveness of antipsoriatic treatment.
Collapse
Affiliation(s)
- A Baran
- a Department of Dermatology and Venereology and
| | - M Swiderska
- b Department of Infectious Diseases and Hepatology , Medical University of Bialystok , Bialystok , Poland
| | - I Flisiak
- a Department of Dermatology and Venereology and
| |
Collapse
|